294190-18-4

Basic information

• Product Name: Benzoic acid, 3-aMino-5-chloro-2-Methyl-, Methyl ester
• Synonyms: Benzoic acid, 3-aMino-5-chloro-2-Methyl-, Methyl ester;Methyl 3-amino-5-chloro-2-methylbenzoate
• CAS NO: 294190-18-4
• Molecular Formula: C₉H₁₀ClNO₂
• Molecular Weight: 199.6342
• Mol File: 294190-18-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Benzoic acid, 3-aMino-5-chloro-2-Methyl-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-aMino-5-chloro-2-Methyl-, Methyl ester(294190-18-4)
• EPA Substance Registry System: Benzoic acid, 3-aMino-5-chloro-2-Methyl-, Methyl ester(294190-18-4)

Safety Data

• Hazardous Substances Data: 294190-18-4(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 3-amino-5-chloro-2-methyl-, methyl ester is a chemical compound with the molecular formula C9H10ClNO2. It is an ester derivative of benzoic acid and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound is known to have antimicrobial and antifungal properties, making it suitable for use in various industrial and medical applications. It is important to handle this compound with care as it may have potential hazards if not used properly.

Upstream product

• 7499-06-1 5-chloro-2-methylbenzoic acid 
• 154257-81-5 5-chloro-2-methyl-3-nitrobenzoic acid 
• 294190-17-3 methyl 5-chloro-2-methyl-3-nitrobenzoate 

Downstream Products

• 1403597-77-2 methyl 3-(((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)amino)-5-chloro-2-methylbenzoate 
• 1403597-67-0 methyl 3-(((cis)-4-((tert-butoxycarbonyl)amino)cyclohexyl)amino)-5-chloro-2-methylbenzoate 
• 1403596-70-2 methyl 5-chloro-3-(cyclobutylamino)-2-methylbenzoate 
• 1403596-75-7 methyl 5-chloro-2-methyl-3-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzoate 
• 1403595-92-5 methyl 5-chloro-3-(cycloheptylamino)-2-methylbenzoate 
• 1403595-77-6 methyl 5-chloro-3-(cyclopentanecarboxamido)-2-methylbenzoate 
• 1403595-38-9 methyl 5-chloro-3-(cyclohexylamino)-2-methylbenzoate 
• 1403595-50-5 methyl 5-chloro-2-methyl-3-((tetrahydro-2H-pyran-4-yl)amino)benzoate 
• 1403596-65-5 methyl 5-chloro-3-((cyclopentylmethyl)amino)-2-methylbenzoate 
• 1403595-31-2 tert-butyl 4-((5-chloro-3-(methoxycarbonyl)-2-methylphenyl)-amino)-piperidine-1-carboxylate 
• 1403596-60-0 methyl 5-chloro-3-(isobutylamino)-2-methylbenzoate 
• 1403590-52-2 5-chloro-3-(cyclohexyl(methyl)amino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methylbenzamide 
• 1403595-39-0 methyl 5-chloro-3-(cyclohexyl(methyl)amino)-2-methylbenzoate 
• 1403595-40-3 C₁₅H₂₀ClNO₂ 

Relevant articles and documents

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

Posttranslational methylation of histones plays a critical role in gene regulation. Misregulation of histone methylation can lead to oncogenic transformation. Enhancer of Zeste homologue 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers. Tazemetostat, an EHZ2 inhibitor in clinical development, has shown activity in both preclinical models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors. Herein we report the structure-activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clinical development. The importance of several methyl groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.

SUBSTITUTED BENZENE COMPOUNDS

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.